

SAUL MARTÍNEZ-HORTA

C/ Casanova 195, Principal 2ª | 08036, Barcelona. Spain | +34 677 53 34 75

Phone: +34 677533475

Email: smartinezho@santpau.cat

H-index: 11

EDUCATION

2001 – 2006 **Psychology** | University of Girona. Spain

2006 – 2008 **Master in Neuropsychology** | Autonomous University of Barcelona. Spain

WORK EXPERIENCE

Current position - 2009 – Now

Clinical and research neuropsychologist | Movement Disorders Unit. Department of Neurology. Hospital de la Santa Creu i Sant Pau. Barcelona. Spain

Language Area Coordinator | European Huntington's Disease Network. 2011 – 2015

Associate professor | Universitat Oberta de Catalunya. Barcelona. Spain. 2014 – 2015

CURRENT CLINICAL AND RESEARCH ACTIVITIES

- Co-coordinator of the multidisciplinary Huntington's disease Clinic at the Sant Pau's Hospital Movement Disorders Unit.

- Clinical Neuropsychology in movement disorders with specific emphasis on Huntington's disease.

- Researcher in the Parkinson's Disease and other Movement Disorders Research Group at the Biomedical Research Institute Sant Pau.

- Co-leader of the Cognitive Phenotype Working Group of the European Huntington's Disease Network

PROJECTS

-Pl17/001885. **Longitudinal study of the clinical and neuroradiological longitudinal correlates associated with huntingtin levels and other CSF and plasmatic biomarkers in Huntington's disease.** *Co-investigator.*

-Pl12/03005. **Development, validation and study of sensibility to change of an alternative version of the Parkinson's Disease – Cognitive Rating Scale.** *Co-investigator*

-NCT01574053. **Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort.** *Co-investigator*

-Pl15/00962. **Functional and anatomical correlates of impulse control disorders and apathy in Parkinson's disease.** *Co-investigator*

-Pl15/0222701/07/2015. **Phenotypes and Haplotypes associated to intermediate alleles in HTT gene of Huntington's disease.** *Co-investigator*

-477-U-201401/07/2014. **Neurophysiological and blood-based biomarkers of cognitive impairment progression in Parkinson's disease.** *Co-investigator*

-Pl10/0149801/01/2011-31/12/2013. **Definition and longitudinal study of mild cognitive impairment in Parkinson's disease: Definition of clinical criteria.** *Co-investigator*

-NCT0159058901/01/2011-01/09/2014. **REGISTRY: An Observational Study of the European Huntington's Disease Network (EHDN).** *Co-investigator*

-NCT02906020. **A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of GZ/SAR402671 in Parkinson's Disease Patients Carrying a Glucocerebrosidase (GBA) Gene Mutation (MOVES-PD).** *Co-investigator*

-NCT02215616. **A Clinical Study in Subjects With Huntington's Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod.** *Co-investigator*

PUBLICATIONS

1. Diago EB, **Martinez-Horta S**, Lasaosa SS, et al. Circadian Rhythm, Cognition, and Mood Disorders in Huntington's Disease. *Journal of Huntington's disease* 2018;7(2):193-198.
2. **Martinez-Horta S**, Perez-Perez J, Sampedro F, et al. Structural and metabolic brain correlates of apathy in Huntington's disease. *Movement disorders : official journal of the Movement Disorder*

Society 2018.

3. Bellosta Diago E, Perez-Perez J, Santos Lasaosa S, et al. Neurocardiovascular pathology in pre-manifest and early-stage Huntington's disease. *European journal of neurology* 2018.
4. Garcia-Gorro C, de Diego-Balaguer R, **Martinez-Horta S**, et al. Reduced striato-cortical and inhibitory transcallosal connectivity in the motor circuit of Huntington's disease patients. *Human brain mapping* 2018;39(1):54-71.
5. Bellosta Diago E, Perez Perez J, Santos Lasaosa S, et al. Circadian rhythm and autonomic dysfunction in presymptomatic and early Huntington's disease. *Parkinsonism & related disorders* 2017;44:95-100.
6. Fernandez-Bobadilla R, **Martinez-Horta S**, Marin-Lahoz J, Horta-Barba A, Pagonabarraga J, Kulisevsky J. Development and validation of an alternative version of the Parkinson's Disease-Cognitive Rating Scale (PD-CRS). *Parkinsonism & related disorders* 2017;43:73-77.
7. Braisch U, **Martinez-Horta S**, MacDonald M, Orth M. Important but not Enough - Information about HD Related Topics and Peer and Professional Support for Young Adults from HD Families. *Journal of Huntington's disease* 2016;5(4):379-387.
8. **Martinez-Horta S**, Sampedro F, Pagonabarraga J, et al. Non-demented Parkinson's disease patients with apathy show decreased grey matter volume in key executive and reward-related nodes. *Brain imaging and behavior* 2017;11(5):1334-1342.
9. **Martinez-Horta S**, Perez-Perez J, van Duijn E, et al. Corrigendum to "Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's disease" [*Parkinsonism Relat. Disord.* 25C (2016) 58-64]. *Parkinsonism & related disorders* 2016;31:161.
10. Cubo E, Ramos-Arroyo MA, **Martinez-Horta S**, Martinez-Descalls A, Calvo S, Gil-Polo C. Clinical manifestations of intermediate allele carriers in Huntington disease. *Neurology* 2016;87(6):571-578.
11. Lopez-Mora DA, Camacho V, Perez-Perez J, et al. Striatal hypometabolism in premanifest and manifest Huntington's disease patients. *European journal of nuclear medicine and molecular imaging* 2016;43(12):2183-2189.
12. **Martinez-Horta S**, Perez-Perez J, van Duijn E, et al. Neuropsychiatric symptoms are very common in premanifest and early stage Huntington's Disease. *Parkinsonism & related disorders* 2016;25:58-64.
13. Ruzafa-Valiente E, Fernandez-Bobadilla R, Garcia-Sanchez C, Pagonabarraga J, **Martinez-**

Horta S, Kulisevsky J. Parkinson's Disease--Cognitive Functional Rating Scale across different conditions and degrees of cognitive impairment. *Journal of the neurological sciences* 2016;361:66-71.

14. Pagonabarraga J, **Martinez-Horta S**, Fernandez de Bobadilla R, et al. Minor hallucinations occur in drug-naive Parkinson's disease patients, even from the premotor phase. *Movement disorders : official journal of the Movement Disorder Society* 2016;31(1):45-52.

15. Lopez-Gongora M, Escartin A, **Martinez-Horta S**, et al. Neurophysiological Evidence of Compensatory Brain Mechanisms in Early-Stage Multiple Sclerosis. *PloS one* 2015;10(8):e0136786.

16. Perez-Perez J, Pagonabarraga J, **Martinez-Horta S**, et al. Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients. *Drugs & aging* 2015;32(5):401-407.

17. Riba J, Valle M, Sampedro F, et al. Telling true from false: cannabis users show increased susceptibility to false memories. *Molecular psychiatry* 2015;20(6):772-777.

18. Gomez-Anson B, Roman E, Fernandez de Bobadilla R, et al. Alterations in cerebral white matter and neuropsychology in patients with cirrhosis and falls. *PloS one* 2015;10(3):e0118930.

19. Perez-Perez J, **Martinez-Horta S**, Pagonabarraga J, Carceller M, Kulisevsky J. Rasagiline for the treatment of parkinsonism in Huntington's disease. *Parkinsonism & related disorders* 2015;21(3):340-342.

20. **Martinez-Horta S**, Riba J, de Bobadilla RF, et al. Apathy in Parkinson's disease: neurophysiological evidence of impaired incentive processing. *The Journal of neuroscience : the official journal of the Society for Neuroscience* 2014;34(17):5918-5926.

21. Gironell A, **Martinez-Horta S**, Aguilar S, et al. Transcranial direct current stimulation of the cerebellum in essential tremor: a controlled study. *Brain stimulation* 2014;7(3):491-492.

22. Fernandez de Bobadilla R, Pagonabarraga J, **Martinez-Horta S**, Pascual-Sedano B, Campolongo A, Kulisevsky J. Parkinson's disease-cognitive rating scale: psychometrics for mild cognitive impairment. *Movement disorders : official journal of the Movement Disorder Society* 2013;28(10):1376-1383.

23. Kulisevsky J, Fernandez de Bobadilla R, Pagonabarraga J, et al. Measuring functional impact of cognitive impairment: validation of the Parkinson's disease cognitive functional rating scale. *Parkinsonism & related disorders* 2013;19(9):812-817.

24. **Martinez-Horta S**, Pagonabarraga J, Fernandez de Bobadilla R, Garcia-Sanchez C, Kulisevsky J. Apathy in Parkinson's disease: more than just executive dysfunction. *Journal of the International Neuropsychological Society* : JINS 2013;19(5):571-582.
25. Villa-Bonomo C, Pagonabarraga J, **Martinez-Horta S**, et al. Short-lasting episodes of prosopagnosia in Parkinson's disease. *Parkinsonism & related disorders* 2013;19(3):375-377.
26. **Martinez-Horta S**, Kulisevsky J. Is all cognitive impairment in Parkinson's disease "mild cognitive impairment"? *J Neural Transm (Vienna)* 2011;118(8):1185
27. Pagonabarraga J, **Martinez-Horta S**, Kulisevsky J. Functional Studies of Parkinson's Disease. In book: *Brain Mapping: An Encyclopedic Reference*, Chapter: Functional Studies of Parkinson's Disease, Publisher: Elsevier, Editors: Arthur W. Toga, pp.713-720. DOI: 10.1016/B978-0-12-397025-1.00081-6
28. **Martinez-Horta S**, Kulisevsky J. Mild Cognitive Impairment in Parkinson's Disease. In book: *Neuropsychiatric symptoms of movement disorders*, Chapter: Mild Cognitive Impairment in Parkinson's Disease, Editors: Springer, pp.29-53. DOI: 10.1007/978-3-319-09537-02
29. Kulisevsky J, **Martinez-Horta S**, Pagonabarraga J. Cognitive assessment in Parkinson's disease. In book: *Neuropsychiatric and Cognitive Changes in Parkinson's Disease and Related Movement Disorders: Diagnosis and Management*, Edition: 1 edition, Chapter: Cognitive assessment in Parkinson's disease, Publisher: Cambridge University Press, Editors: Dag Aarsland, Jeffrey Cummings, Daniel Weintraub, K. Ray Chaudhuri, pp.54-65. DOI: 10.1017/CBO9781139856669.006

LANGUAGE SKILLS

- Spanish – C2 (Native)
- Catalan – C2 (Native)
- English – C1